The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

NCT04552223: A phase II study of nivolumab plus BMS-986016 (relatlimab) in patients with metastatic uveal melanoma (UM) (CA224-094).

Jose  Lutzky

Consulting or Advisory Role - Castle Biosciences; Iovance Biotherapeutics; Regeneron; Replimune

Research Funding - Bristol-Myers Squibb (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst); Vyriad (Inst)

Lynn G.  Feun

Research Funding - Merck Sharp & Dohme (Inst)

Norma  Magallanes

No Relationships to Disclose

Deukwoo  Kwon

No Relationships to Disclose

J. William  Harbour

No Relationships to Disclose